Cargando…

Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo

BACKGROUND: Rhodojaponin III (RJ-III) is a bioactive diterpenoid, which is mainly found in Rhododendron molle G. Don (Ericaceae), a potent analgesia in traditional Chinese medicine with several years of clinical applications in the country. However, its clinical use is limited by its acute toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Qingyun, Yang, Jian, Sun, Shuigen, Zhao, Jingyi, Liang, Shuang, Feng, Yi, Liu, Minchen, Zhang, Jiquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392492/
https://www.ncbi.nlm.nih.gov/pubmed/35996527
http://dx.doi.org/10.2147/IJN.S362443
_version_ 1784771073619787776
author Yang, Qingyun
Yang, Jian
Sun, Shuigen
Zhao, Jingyi
Liang, Shuang
Feng, Yi
Liu, Minchen
Zhang, Jiquan
author_facet Yang, Qingyun
Yang, Jian
Sun, Shuigen
Zhao, Jingyi
Liang, Shuang
Feng, Yi
Liu, Minchen
Zhang, Jiquan
author_sort Yang, Qingyun
collection PubMed
description BACKGROUND: Rhodojaponin III (RJ-III) is a bioactive diterpenoid, which is mainly found in Rhododendron molle G. Don (Ericaceae), a potent analgesia in traditional Chinese medicine with several years of clinical applications in the country. However, its clinical use is limited by its acute toxicity and poor pharmacokinetic profiles. To reduce such limitations, the current study incorporated RJ-III into the colloidal drug delivery system of hydroxypropyl trimethyl ammonium chloride chitosan (HACC)-modified solid lipid nanoparticles (SLNs) to improve its sustained release and antinociceptive effects in vivo for oral delivery. RESULTS: The optimized RJ-III@HACC-SLNs were close to spherical, approximately 134 nm in size, and with a positive zeta potential. In vitro experiments showed that RJ-III@HACC-SLNs were stable in the simulated gastric fluid and had a prolonged release in PBS (pH = 6.8). Pharmacokinetic results showed that after intragastric administration in mice, the relative bioavailability of RJ-III@HACC-SLNs was 87.9%. Further, it was evident that the peak time, half-time, and mean retention time of RJ-III@HACC-SLNs were improved than RJ-III after the administration. In addition, pharmacodynamic studies revealed that RJ-III@HACC-SLNs markedly reduced the acetic acid, hot, and formalin-induced nociceptive responses in mice (P < 0.001), and notably increased the analgesic time (P < 0.01). Moreover, RJ-III@HACC-SLNs not only showed good biocompatibility with Caco-2 cells in vitro but its LD(50) value was also increased by 1.8-fold as compared with that of RJ-III in vivo. CONCLUSION: These results demonstrated that RJ-III@HACC-SLNs improved the pharmacokinetic characteristics of the RJ-III, thereby exhibiting toxicity-attenuating potential and antinociceptive enhancing properties. Consequently, HACC-SLNs loaded with RJ-III could become a promising oral formulation for pain management that deserves further investigation in the future.
format Online
Article
Text
id pubmed-9392492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93924922022-08-21 Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo Yang, Qingyun Yang, Jian Sun, Shuigen Zhao, Jingyi Liang, Shuang Feng, Yi Liu, Minchen Zhang, Jiquan Int J Nanomedicine Original Research BACKGROUND: Rhodojaponin III (RJ-III) is a bioactive diterpenoid, which is mainly found in Rhododendron molle G. Don (Ericaceae), a potent analgesia in traditional Chinese medicine with several years of clinical applications in the country. However, its clinical use is limited by its acute toxicity and poor pharmacokinetic profiles. To reduce such limitations, the current study incorporated RJ-III into the colloidal drug delivery system of hydroxypropyl trimethyl ammonium chloride chitosan (HACC)-modified solid lipid nanoparticles (SLNs) to improve its sustained release and antinociceptive effects in vivo for oral delivery. RESULTS: The optimized RJ-III@HACC-SLNs were close to spherical, approximately 134 nm in size, and with a positive zeta potential. In vitro experiments showed that RJ-III@HACC-SLNs were stable in the simulated gastric fluid and had a prolonged release in PBS (pH = 6.8). Pharmacokinetic results showed that after intragastric administration in mice, the relative bioavailability of RJ-III@HACC-SLNs was 87.9%. Further, it was evident that the peak time, half-time, and mean retention time of RJ-III@HACC-SLNs were improved than RJ-III after the administration. In addition, pharmacodynamic studies revealed that RJ-III@HACC-SLNs markedly reduced the acetic acid, hot, and formalin-induced nociceptive responses in mice (P < 0.001), and notably increased the analgesic time (P < 0.01). Moreover, RJ-III@HACC-SLNs not only showed good biocompatibility with Caco-2 cells in vitro but its LD(50) value was also increased by 1.8-fold as compared with that of RJ-III in vivo. CONCLUSION: These results demonstrated that RJ-III@HACC-SLNs improved the pharmacokinetic characteristics of the RJ-III, thereby exhibiting toxicity-attenuating potential and antinociceptive enhancing properties. Consequently, HACC-SLNs loaded with RJ-III could become a promising oral formulation for pain management that deserves further investigation in the future. Dove 2022-08-16 /pmc/articles/PMC9392492/ /pubmed/35996527 http://dx.doi.org/10.2147/IJN.S362443 Text en © 2022 Yang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yang, Qingyun
Yang, Jian
Sun, Shuigen
Zhao, Jingyi
Liang, Shuang
Feng, Yi
Liu, Minchen
Zhang, Jiquan
Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo
title Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo
title_full Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo
title_fullStr Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo
title_full_unstemmed Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo
title_short Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo
title_sort rhodojaponin iii-loaded chitosan derivatives-modified solid lipid nanoparticles for multimodal antinociceptive effects in vivo
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392492/
https://www.ncbi.nlm.nih.gov/pubmed/35996527
http://dx.doi.org/10.2147/IJN.S362443
work_keys_str_mv AT yangqingyun rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT yangjian rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT sunshuigen rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT zhaojingyi rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT liangshuang rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT fengyi rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT liuminchen rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo
AT zhangjiquan rhodojaponiniiiloadedchitosanderivativesmodifiedsolidlipidnanoparticlesformultimodalantinociceptiveeffectsinvivo